Recursion Pharmaceuticals (RXRX) Gross Profit (2021 - 2026)

Recursion Pharmaceuticals has reported Gross Profit for 6 years, with the latest figure at -$6.0 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 15.05% year-over-year to -$6.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.8 million (up 23.3% YoY), and the FY2025 full-year result was $3.7 million, down 72.59% from the prior year.
• Gross Profit for Q1 2026 stood at -$6.0 million, down from $21.3 million in the prior quarter.
• The five-year high for Gross Profit was $21.3 million in Q4 2025, with the low at -$9.5 million in Q3 2025.
• Historically, Gross Profit has averaged $286294.1 across 5 years, with a median of -$344000.0 in 2023.
• The largest YoY upside for Gross Profit was 4170.64% in 2024 against a maximum downside of 916.63% in 2024.
• Recursion Pharmaceuticals' Gross Profit stood at $2.8 million in 2022, then plunged by 64.39% to $1.0 million in 2023, then tumbled by 916.63% to -$8.2 million in 2024, then jumped by 357.8% to $21.3 million in 2025, then sank by 128.3% to -$6.0 million in 2026.
• The last three Gross Profit figures came in at -$6.0 million (Q1 2026), $21.3 million (Q4 2025), and -$9.5 million (Q3 2025), per Business Quant data.